Trappin‐2/Elafin: a novel innate anti‐human immunodeficiency virus‐1 molecule of the human female reproductive tract
Open Access
- 7 January 2010
- journal article
- Published by Wiley in Immunology
- Vol. 129 (2), 207-219
- https://doi.org/10.1111/j.1365-2567.2009.03165.x
Abstract
Trappin-2/Elafin is a serine protease inhibitor that plays a major role as an anti-inflammatory mediator at mucosal surfaces. In addition, Trappin-2/Elafin has antibacterial activity against Gram-positive and Gram-negative bacterial and fungal pathogens. In this study we examined the production of Trappin-2/Elafin by epithelial cells from the human upper and lower female reproductive tract as well as its activity as an anti-human immunodeficiency virus (HIV)-1 molecule. We found that primary uterine, Fallopian tube, cervical and ectocervical epithelial cells produce Trappin-2/Elafin constitutively and that production of Trappin-2/Elafin is enhanced following stimulation with Poly(I:C), especially by the uterine cells. Given the presence of Trappin-2/Elafin in the reproductive tract, we tested the ability of recombinant Trappin-2/Elafin to inhibit HIV-1, an important sexually transmitted pathogen. We found that recombinant Trappin-2/Elafin was able to inhibit both T-cell-tropic X4/IIIB and macrophage-tropic R5/BaL HIV-1 in a dose-dependent manner. The inhibitory activity was observed when virus was incubated with Trappin-2/Elafin but not when Trappin-2/Elafin was added to cells either before infection or after infection. This suggests that the mechanism of inhibition is likely to be a direct interaction between HIV-1 and Trappin-2/Elafin. Additionally, we measured the levels of secreted Trappin-2/Elafin in cervico-vaginal lavages (CVL) from both HIV-positive and HIV-negative women and found that average levels of secreted Trappin-2/Elafin were higher in the CVL from HIV-negative women, although the values did not reach statistical significance. We also found that women at the secretory phase of the menstrual cycle produced more Trappin-2/Elafin in CVL relative to women at the proliferative phase of the menstrual cycle. Our data suggest that Trappin-2/Elafin might be an important endogenous microbicide of the female reproductive tract that is protective against HIV-1.Keywords
This publication has 71 references indexed in Scilit:
- A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycleAIDS, 2008
- Antiviral responses of human Fallopian tube epithelial cells to toll-like receptor 3 agonist poly(I:C)Fertility and Sterility, 2008
- A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiologyBiological Chemistry, 2008
- Increased Levels of HIV-1-Infected Cells in Endocervical Secretions After the Luteinizing Hormone SurgeJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted InfectionsAAPS PharmSciTech, 2008
- Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trialThe Lancet, 2007
- Microbicide trial screeches to a haltJCI Insight, 2007
- Effect of oestradiol on PAMP‐mediated CCL20/MIP‐3α production by mouse uterine epithelial cells in cultureImmunology, 2006
- Human Immunodeficiency Virus Type 1 Genomic RNA Sequences in the Female Genital Tract and Blood: Compartmentalization and Intrapatient RecombinationJournal of Virology, 2005
- Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia.JCI Insight, 1996